FDA says Novo Nordisk's TV ad for obesity pill includes 'false or misleading' claims

In this article

The Food and Drug Administration said Novo Nordisk

’s TV advertisement for its newly launched Wegovy pill for obesity included “false or misleading” claims about the medicine’s abilities and benefits to patients.

In a letter to Novo dated Feb. 5, the FDA said the ad misbrands the oral drug, making its distribution a violation of federal law. The agency requested that the drugmaker take immediate action to address the violations, which could include ceasing all ads containing misleading claims.

In a statement on Monday, Novo Nordisk confirmed that it received the letter and clarified that the ad has been running since the pill’s launch, but is not the company’s Super Bowl spot.

FDA says Novo Nordisk's TV ad for obesity pill includes 'false or misleading' claims

Other newsrooms on this story

Related reading

FDA approves Wegovy weight-loss pill from Novo Nordisk

US regulators approve Wegovy pill, first oral medication to treat obesity

FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk

FDA: Novo Nordisk failed to report deaths of weight-loss drug patients

Drugmaker Novo Nordisk slashes Wegovy sales forecasts, blaming compounding

FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk…